<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02471859</url>
  </required_header>
  <id_info>
    <org_study_id>GB29751</org_study_id>
    <secondary_id>2015-000560-33</secondary_id>
    <nct_id>NCT02471859</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Participants</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending, Single- and Multiple-Oral-Dose, Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending, Single- and
      Multiple-Oral Dose, Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy
      Subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing an adverse event</measure>
    <time_frame>Up to approximately 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) for GDC-3280</measure>
    <time_frame>Up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) for GDC-3280</measure>
    <time_frame>Up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total serum clearance for GDC-3280</measure>
    <time_frame>Up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution for GDC-3280</measure>
    <time_frame>Up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life for GDC-3280</measure>
    <time_frame>Up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum GDC-3280 concentration-time data by dosing group</measure>
    <time_frame>Up to 4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Part A: GDC-3280</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in multiple cohorts and treatment periods will receive single doses of GDC-3280 under fed/fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in multiple cohorts and treatment periods will receive single doses of placebo under fed/fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: GCD-3280</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in different cohorts will receive GDC-3280 in multiple ascending doses under fed/fasting conditions.\n</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in different cohorts will receive placebo in multiple ascending doses under fed/fasting conditions.\n</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-3280</intervention_name>
    <description>GDC-3280 at various doses, depending on the cohort and treatment period</description>
    <arm_group_label>Part A: GDC-3280</arm_group_label>
    <arm_group_label>Part B: GCD-3280</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo at various doses, depending on the cohort and treatment period</description>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_label>Part B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is male or female, using highly effective contraception

          -  Has a body mass index (BMI) 18.0 to 30.0 kg/m2, inclusive

          -  Is in good general health

          -  Having signed informed consent, is willing and able to comply with requirements of the
             study

        Exclusion Criteria:

          -  Does not satisfy all screening criteria per protocol

          -  Is employed by or related to any personnel involved in the trial

          -  Has any history or condition that per protocol or in the opinion of the investigator
             could compromise the participant's safety or analysis of results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2015</study_first_submitted>
  <study_first_submitted_qc>June 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2015</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

